Skip to main content
Top
Published in: Metabolic Brain Disease 4/2024

02-02-2024 | Atypical Parkinsonism | Original Article

Identification of metabolic pathways and key genes associated with atypical parkinsonism using a systems biology approach

Authors: Amanda Pasqualotto, Vinícius da Silva, Felipe Mateus Pellenz, Artur Francisco Schumacher Schuh, Ida Vanessa Doederlein Schwartz, Marina Siebert

Published in: Metabolic Brain Disease | Issue 4/2024

Login to get access

Abstract

Atypical parkinsonism (AP) is a group of complex neurodegenerative disorders with marked clinical and pathophysiological heterogeneity. The use of systems biology tools may contribute to the characterization of hub-bottleneck genes, and the identification of its biological pathways to broaden the understanding of the bases of these disorders. A systematic search was performed on the DisGeNET database, which integrates data from expert curated repositories, GWAS catalogues, animal models and the scientific literature. The tools STRING 11.0 and Cytoscape 3.8.2 were used for analysis of protein-protein interaction (PPI) network. The PPI network topography analyses were performed using the CytoHubba 0.1 plugin for Cytoscape. The hub and bottleneck genes were inserted into 4 different sets on the InteractiveVenn. Additional functional enrichment analyses were performed to identify Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and gene ontology for a described set of genes. The systematic search in the DisGeNET database identified 485 genes involved with Atypical Parkinsonism. Superimposing these genes, we detected a total of 31 hub-bottleneck genes. Moreover, our functional enrichment analyses demonstrated the involvement of these hub-bottleneck genes in 3 major KEGG pathways. We identified 31 highly interconnected hub-bottleneck genes through a systems biology approach, which may play a key role in the pathogenesis of atypical parkinsonism. The functional enrichment analyses showed that these genes are involved in several biological processes and pathways, such as the glial cell development, glial cell activation and cognition, pathways were related to Alzheimer disease and Parkinson disease. As a hypothesis, we highlight as possible key genes for AP the MAPT (microtubule associated protein tau), APOE (apolipoprotein E), SNCA (synuclein alpha) and APP (amyloid beta precursor protein) genes.
Appendix
Available only for authorised users
Literature
go back to reference Deutschländer AB, Ross OA, Dickson DW, Wszolek ZK (2018) Atypical parkinsonian syndromes: a general neurologist’s perspective. Eur J Neurol Deutschländer AB, Ross OA, Dickson DW, Wszolek ZK (2018) Atypical parkinsonian syndromes: a general neurologist’s perspective. Eur J Neurol
go back to reference Dietschy JM, Turley SD (2004) Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res Dietschy JM, Turley SD (2004) Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res
go back to reference Foguem C, Manckoundia P (2018) Lewy Body Disease: clinical and pathological overlap syndrome between synucleinopathies (Parkinson Disease) and tauopathies (Alzheimer Disease). Curr Neurol Neurosci Rep 18 Foguem C, Manckoundia P (2018) Lewy Body Disease: clinical and pathological overlap syndrome between synucleinopathies (Parkinson Disease) and tauopathies (Alzheimer Disease). Curr Neurol Neurosci Rep 18
go back to reference Giagkou N, Stamelou M (2018) Therapeutic management of the overlapping syndromes of atypical parkinsonism. CNS Drugs Giagkou N, Stamelou M (2018) Therapeutic management of the overlapping syndromes of atypical parkinsonism. CNS Drugs
go back to reference Lill CM (2016) Genetics of Parkinson’s disease. Mol Cell Probes Lill CM (2016) Genetics of Parkinson’s disease. Mol Cell Probes
go back to reference Minoru Kanehisa and Susumu Goto (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27–30CrossRef Minoru Kanehisa and Susumu Goto (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27–30CrossRef
go back to reference Miryala SK, Anbarasu A, Ramaiah S (2018) Discerning molecular interactions: A comprehensive review on biomolecular interaction databases and network analysis tools. Gene Miryala SK, Anbarasu A, Ramaiah S (2018) Discerning molecular interactions: A comprehensive review on biomolecular interaction databases and network analysis tools. Gene
go back to reference Scholz SW, Bras J (2015) Genetics underlying atypical parkinsonism and related neurodegenerative disorders. Int J Mol Sci Scholz SW, Bras J (2015) Genetics underlying atypical parkinsonism and related neurodegenerative disorders. Int J Mol Sci
go back to reference Vance JE (2012) Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. DMM Disease Models and Mechanisms Vance JE (2012) Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. DMM Disease Models and Mechanisms
go back to reference Vidal M (2009) A unifying view of 21st century systems biology. FEBS Lett Vidal M (2009) A unifying view of 21st century systems biology. FEBS Lett
go back to reference Wenning GK, Stankovic I, Vignatelli L et al (2022) The Movement Disorder Society Criteria for the diagnosis of multiple system atrophy. Mov Disord 37:1131–1148CrossRefPubMedPubMedCentral Wenning GK, Stankovic I, Vignatelli L et al (2022) The Movement Disorder Society Criteria for the diagnosis of multiple system atrophy. Mov Disord 37:1131–1148CrossRefPubMedPubMedCentral
Metadata
Title
Identification of metabolic pathways and key genes associated with atypical parkinsonism using a systems biology approach
Authors
Amanda Pasqualotto
Vinícius da Silva
Felipe Mateus Pellenz
Artur Francisco Schumacher Schuh
Ida Vanessa Doederlein Schwartz
Marina Siebert
Publication date
02-02-2024
Publisher
Springer US
Published in
Metabolic Brain Disease / Issue 4/2024
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI
https://doi.org/10.1007/s11011-024-01342-7

Other articles of this Issue 4/2024

Metabolic Brain Disease 4/2024 Go to the issue